Aurinia Pharmaceuticals Inc. reiterated revenue guidance for 2023. For the period, company reiterates net product revenue guidance in the range of $120-$140 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | +2.82% |
|
+5.16% | -35.43% |
07-01 | Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell Small Cap Comp Value Index | CI |
07-01 | Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 2500 Value Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.43% | 809M | |
+20.39% | 127B | |
+24.43% | 117B | |
+25.44% | 27.67B | |
-18.11% | 20.33B | |
-15.17% | 16.79B | |
-14.88% | 15.63B | |
+12.67% | 14.84B | |
-47.10% | 14.65B | |
+56.25% | 14.43B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for 2023